Establishment of a quantitative assay of abnormal glycolipid expression in endometrial cells, and its diagnostic value for endometrial carcinoma

Yoichi Kobayashi, Katsumi Tsukazaki, Kaneyuki Kubushiro, Motoko Sakayori, Shiro Nozawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We developed a new quantitative method for detecting abnormal glycolipid expression in endometrial cells using a monoclonal antibody (MSN-1) and analyzed the glycolipid antigen recognized by MSN-1 in 173 clinical endometrial cell samples (66 normal endometria, 39 endometrial hyperplasias, and 68 endometrial adenocarcinomas). The mean glycolipid antigen levels in normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 0.42 ± 137, 2.13 ± 3.84, and 19.4 ± 25.8 (mean ± SD) units, respectively. If the cutoff rate of this assay was fixed at 1.8 units, the positivity rates for patients with normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 6.1% (4/66). 28.2% (11/39), and 76.5% (52/68), respectively. In 35 endometrial carcinoma patients, endometrial smears were simultaneously performed, and there were 22 positive smears (62.9%). When the cytological diagnosis was combined with our assay, 943% (33/35) of the carcinomas were detected. Thus, this assay seems to be a supplementary diagnostic method for endometrial carcinoma.

Original languageEnglish
Pages (from-to)749-754
Number of pages6
JournalClinical Cancer Research
Volume2
Issue number4
Publication statusPublished - 1996 Apr 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Establishment of a quantitative assay of abnormal glycolipid expression in endometrial cells, and its diagnostic value for endometrial carcinoma'. Together they form a unique fingerprint.

  • Cite this